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Background: Cognitive impairment is a distressing, disruptive, and potentially debilitating symptom 
that can occur as a direct result of cancer or its treatment. National organizations have identified 
cognitive impairment as a challenge many survivors face and call for research to address this prob-
lem. Despite the priority, research is still relatively limited and questions remain unanswered about 
prevalence and impact on survivors, as well as coping strategies and effective treatment options 
available to address this potentially debilitating problem. 
Objectives: The purpose of this article is to (a) analyze the prevalence and types of cognitive impair-
ment that commonly affect survivors; (b) delineate the impact that cognitive impairment after cancer and cancer treatment 
has on self-esteem, social relationships, work ability, and overall quality of life among survivors; and (c) synthesize and 
appraise commonly used coping strategies used by survivors to address cognitive impairment and evidence-based interven-
tions that may be incorporated into clinical practice. 
Methods: A comprehensive review and synthesis of the literature was conducted. 
Findings: Evidence-based interventions to address cognitive changes after cancer and cancer treatment are limited. 
However, emerging research has demonstrated that nonpharmacologic treatments, such as cognitive training, are likely 
to be effective. 
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T 
he study of cognitive impairment as a late effect 
of cancer and its treatment has become a national 
research priority. The President’s Cancer Panel, the 
National Cancer Institute Office of Cancer Survivor-
ship, and the National Comprehensive Cancer Net-
work Survivorship Panel have all identified emerging chronic 
and late effects of cancer and its treatment, such as cognitive 
impairment, as top research priorities (Hewitt, Greenfield, & 
Stovall, 2005). The National Coalition of Cancer Survivorship, 
a survivor-led cancer advocacy group, also has identified cog-
nitive impairment as a challenge facing many cancer survivors 
and calls for research to address this problem. The Oncology 
Nursing Society Research Priority Survey identified cogni-
tive impairment as one of the most distressing and difficult 
symptoms to treat (LoBiondo-Wood et al., 2014). Despite the 
priority, research in this area is relatively limited, with many 
unanswered questions regarding the prevalence and impact on 
survivors as well as insufficient data to guide evidence-based 
interventions (Vardy, Wefel, Ahles, Tannock, & Schagen, 2008; 
Von Ah, Jansen, Allen, Schiavone, & Wulff, 2011; Von Ah, Storey, 
Jansen, & Allen, 2013). 
Definition of Cognitive Impairment 
Cognitive impairment has been defined as those cognitive 
changes that negatively affect higher-order mental processes 
(Hess & Insel, 2007). Although no single neurocognitive sig-
nature of cancer- and cancer treatment–related effects stands 
out (Castellon, Silverman, & Ganz, 2005), deficits in attention, 
memory, speed of processing, language (word finding), and ex-
ecutive functioning (problem solving) appear to be most com-
mon (Anderson-Hanley, Sherman, Riggs, Agocha, & Compas, 
2003; Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005; 
Vardy et al., 2008). Cognitive deficits following diagnosis and 
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treatment of cancer may be subtle, yet may have a significant 
impact on quality of life in cancer survivors (Mehnert et al., 
2007; Von Ah, Russell, Storniolo, & Carpenter, 2009). 
Risk Factors 
The exact etiology of cognitive deficits in cancer survivors is 
not fully understood and most likely is thought to be multifacto-
rial (Bender & Thelen, 2013; Merriman, Von Ah, Miaskowski, 
& Aouizerat, 2013). Briefly, in cancer survivors, tumor- and/
or treatment-related factors may directly or indirectly affect 
cognitive functioning through one or more of the following 
mechanisms: neurotoxic injury in the brain, microvascular 
injury, secondary central and/or systemic inflammatory pro-
cesses, or dysregulation of the hypothalamic–pituitary–adrenal 
(HPA) axis, resulting in changes in endogenous hormones 
(estrogen and serotonin) (Merriman et al., 2013). In addition, 
it has been hypothesized that cancer treatment may accelerate 
cognitive aging by influencing aging at a cellular level, including 
inflammation, DNA damage, oxidative stress, telomere length, 
and cell senescence (Ahles, Root, & Ryan, 2012; Mandelblatt et 
al., 2013). Individual differences in age, education level, intel-
ligence, menopausal status, comorbid conditions, medication 
usage, and genetics also may contribute to cognitive deficits in 
cancer survivors (Bender & Thelen, 2013). Cognitive deficits 
also may be compounded by other related symptoms, including 
fatigue, depression, and anxiety (Bender, Ergyn, Rosenzweig, 
Cohen, & Sereika, 2005; Bender & Thelen, 2013). A summary of 
cancer- and treatment-related and non-cancer treatment–related 
factors that may influence an individual’s risk for cognitive 
impairment are displayed in Figure 1 (Bender & Thelen, 2013; 
Mandelblatt et al., 2013; National Comprehensive Cancer Net-
work, 2013). The complexity associated with cognitive changes 
after cancer and cancer treatment contribute to the difficulty of 
understanding and effectively treating this symptom (Bender 
& Thelen, 2013). 
Scope of the Problem
Seventeen percent (van Dam et al., 1998) to 75% (Wieneke 
& Dienst, 1995) of survivors report some level of cognitive 
impairment (Anderson-Hanley et al., 2003; Falleti, Sanfilippo, 
Maruff, Weih, & Phillips, 2005; Jansen et al., 2005; Stewart, 
Bielajew, Collins, Parkinson, & Tomiak, 2006; van Dam et al., 
1998; Wieneke & Dienst, 1995). In Von Ah, Harvison, et al. 
(2009), the author’s group found clinically significant memory 
deficits in 44% of breast cancer survivors (n = 52) who were, on 
average, 4.6 years (SD = 2.76) post-treatment. Five meta-analyses 
have also documented cognitive deficits that survivors experi-
ence, suggesting that impairments in memory, attention and 
concentration, speed of processing, and executive functioning 
are most common (Anderson-Hanley et al., 2003; Falleti et al., 
2005; Jansen et al., 2005; Jim et al., 2012; Stewart et al., 2006). 
Although results of some prospective studies suggest cogni-
tive impairment may attenuate over time (Jenkins et al., 2006; 
Tchen et al., 2003; Wefel, Lenzi, Theriault, Davis, & Meyers, 
2004), researchers have found that a substantial number of sur-
vivors continue to have objectively measured memory deficits 
for 5, 10, and even as long as 20 years post-treatment (Ahles et 
al., 2002; Jenkins et al., 2006; Koppelmans et al., 2012; Wefel 
et al., 2004). 
In addition, researchers have explored cognitive changes as-
sociated with cancer using multiple neuroimaging techniques 
(Holohan, Von Ah, McDonald, & Saykin, 2013). Electrophysi-
ologic and imaging studies reveal differences in central ner-
vous system structure and function among survivors exposed 
to chemotherapy compared to baseline prechemotherapy or 
control participants (Brown et al., 1998; Ferguson, McDonald, 
Saykin, & Ahles, 2007; Inagaki et al., 2007; Kreukels et al., 2005; 
Saykin, Ahles, & McDonald, 2003; Schagen, Hamburger, Muller, 
Boogerd, & van Dam, 2001; Silverman et al., 2007). Results 
from imaging studies also have documented reduced regional 
volumes of gray and white matter, with studies demonstrating 
both short-term (Brown et al., 1998; Ferguson, McDonald, et al., 
2007; Inagaki et al., 2007) and long-term effects (Saykin et al., 
2003). In addition, in a review of the empirical literature, Ho-
lohan et al. (2013) identified 35 separate neuroimaging studies 
and noted that the majority identified structural and/or func-
tional alterations which also were accompanied by increases in 
self-reported cognitive concerns, neuropsychological testing 
deficits, or both. Taken together, findings from these studies 
provide clear and convincing evidence that cognitive deficits 
are prevalent after cancer and cancer treatment. 
Impact on Quality of Life and Work-Related Outcomes
Cognitive impairment can dramatically affect quality of life 
in survivors (Mehnert et al., 2007; Myers, 2013; Von Ah, Haber-
mann, Carpenter, & Schneider, 2013). In a survey of 471 sur-
vivors, 62% stated that cognitive problems were disruptive to 
their functioning and relationships at home and at work (Hede, 
2008). In qualitative interviews with 22 breast cancer survivors, 
cognitive impairment affected survivors’ self-confidence, self-es-
teem, social relationships, and perceived work ability (Von Ah, 
Habermann, et al., 2013). Survivors related that they often were 
embarrassed when they could not remember names, dates, or 
places and often would withdraw from social situations. In 
addition, many identified that dealing with cognitive changes 
Cancer- and Treatment-Related Factors:
•	 Cancer type, staging, disease trajectory: central nervous system pri-
mary or metastatic disease
•	 Cancer treatment: chemotherapy, intrathecal chemotherapy, brain 
irradiation
Non-Cancer Treatment–Related Factors:
•	 Demographic factors: age, education level, intelligence
•	 Life stage: menopausal status 
•	 Comorbidities: cardiac toxicity, respiratory diseases
•	 Other medications: prescription, over-the-counter supplements
•	 Psychological distress: anxiety, depression
•	 Symptom burden: fatigue, sleep disturbances
•	 Genetics
FIGURE 1. Factors That Influence Cognitive Impairment 
Risk
Note. Based on information from Bender & Thelen, 2013; Mandelblatt 
et al., 2013; National Comprehensive Cancer Network, 2013.
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after cancer and cancer treatment was most difficult when 
family, friends, or healthcare providers did not acknowledge 
or validate their concerns. Previous work by Von Ah, Russell, 
et al. (2009) with 135 African American (47%) and Caucasian 
(53%) breast cancer survivors also demonstrated that subjec-
tive cognitive impairment was related to poorer health-related 
quality of life, including more depressive symptoms, lower 
well-being, poorer physical functioning, and greater fatigue. 
Results from multiple studies also have shown that cognitive 
impairment, as demonstrated on objective neuropsychological 
tests, is associated with higher levels of depressive symptoms, 
fatigue, and anxiety (Bender et al., 2006; Cimprich, 1992, 1993; 
Mehnert et al., 2007; Stewart et al., 2008; Wefel et al., 2004). 
In preliminary work conducted by Von Ah et al. (2010), which 
included 444 breast cancer survivors compared to 355 healthy 
women, the authors found that cognitive impairment on neu-
ropsychological tests (deficits in immediate [short-term] and 
delayed memory, processing speed, and executive functioning) 
was significantly related to depressive symptoms and fatigue. 
Findings are supported by research results in which cognitive 
impairment commonly co-occurs with fatigue and depressive 
symptoms across the cancer trajectory (Bender et al., 2005; 
Bender & Thelen, 2013). In addition, many researchers have 
demonstrated that cognitive impairment affects perceived work 
ability in survivors (Calvio, Peugeot, Bruns, Todd, & Feuerstein, 
2010; de Boer et al., 2008; Feuerstein, Hansen, Calvio, Johnson, 
& Ronquillo, 2007; Hansen, Feuerstein, Calvio, & Olsen, 2008; 
Pryce, 2007; Taskila, Martikainen, Hietanen, & Lindbohm, 2007; 
Von Ah, Habermann, et al., 2013). In a large cohort study of 
1,490 employed survivors and 2,796 reference participants, sur-
vivors had significantly lower levels of perceived work ability 
than healthy controls (Lindbohm et al., 2012). Perceived work 
ability, or the capability to manage job demands (Ilmarinen & 
Tuomi, 2004), has been associated with job stress (Kinnunen, 
Parkatti, & Rasku, 1994), and several studies have confirmed 
that poor work ability predicts loss of work productivity, retire-
ment intentions, long-term absence, early retirement, need for 
rehabilitation, and work disability (Alavinia, de Boer, van Duiv-
enbooden, Frings-Dresen, & Burdorf, 2009; Kuoppala, Lam-
minpaa, Vaananen-Tomppo, & Hinkka, 2011; Salonen, Arola, 
Nygard, Huhtala, & Koivisto, 2003; Sell et al., 2009). Overall, 
research has consistently documented the significant and nega-
tive impact of cancer- and cancer treatment–related cognitive 
impairment on survivor’s self-confidence, social relationships, 
quality of life, and work-related outcomes (Myers, 2013). 
Coping Strategies to Address Cognitive Impairment
Although cognitive impairment after cancer and cancer 
treatment is a prevalent and significant problem, little research 
has focused on addressing these cognitive changes. Interviews 
with survivors provide some insight regarding how survivors 
live with and manage cognitive changes after cancer (Myers, 
2013; Von Ah, Storey, et al., 2013). Figure 2 displays a summary 
of positive and potentially negative coping strategies used by 
survivors to address cognitive impairment. The majority of the 
research reviewed identified positive methods for coping with 
cognitive changes after cancer. In previous work (Von Ah, 
Storey, et al., 2013), the author’s group was able to identify and 
classify these positive coping strategies into five overarching 
and distinct categories: organizational and self-management, 
management of the physical environment, management of the 
social environment, stress and attentional fatigue-reducing 
methods, and engaging in mind-stimulating activities. However, 
the literature also reported that survivors identified potentially 
negative coping strategies, such as avoiding social activities, 
avoiding substantive social interactions, and leaving demanding 
employment situations (Myers, 2013). Although removal from a 
stressful social or work situation may be appropriate depending 
on the context and extent used, these avoidant strategies may 
not produce the long-term positive adjustment that is necessary 
to address cognitive changes after cancer. 
Interventions for Cognitive Changes After Cancer  
and Its Treatment
Evidence-based interventions for cognitive impairment after 
cancer and cancer treatment remain limited. Researchers have 
explored pharmacologic and nonpharmacologic approaches to 
address cancer- and cancer treatment–related cognitive impair-
ment (Von Ah et al., 2011; Von Ah, Jansen, & Allen, 2014). Table 
1 displays the pharmacologic interventions trialed, including 
the use of donepezil, an acetylcholinesterase inhibitor often 
used for Alzheimer disease (Jatoi et al., 2005; Shaw et al., 2006); 
methylphenidate, a psychostimulant often used in children 
with attention deficit hyperactivity disorder (Bruera, Miller, 
Macmillan, & Kuehn, 1992; Butler et al., 2007; Escalante et 
al., 2014; Gagnon, Low, & Schreier, 2005; Gehring et al., 2012; 
Lower et al., 2009; Mar Fan et al., 2008; Meyers, Weitzner, Val-
entine, & Levin, 1998; Schwartz, Thompson, & Masood, 2002); 
memantine, an N-methyl-D-aspartate receptor antagonist, 
which has been shown to be neuroprotective in preclinical tri-
als (Brown et al., 2013); and modafinil, a psychostimulant often 
used for narcolepsy (Blackhall, Petroni, Shu, Baum, & Farace, 
2009; Gehring et al., 2012; Kohli et al., 2009; Lundorff, Jonsson, 
& Sjogren, 2009). Table 2 highlights the nonpharmacologic 
treatments used to address cognitive impairment, including 
Examples of Positive Coping Strategies
•	 Writing things down
•	 Using reminder cues (e.g., calendar, notes)
•	 Develop a routine schedule.
•	 Focus on one task at a time; do not rush tasks.
•	 Give oneself permission to make mistakes.
•	 Keep items and belongings in the same place.
•	 Surround self with supportive family and friends.
•	 Ask for help when necessary.
•	 Humor
•	 Seek stress-reduction activities, such as exercise, meditation, yoga.
•	 Obtain plenty of rest; adequate sleep
•	 Mind-stimulating activities: crossword puzzles, word games, sudoku
Examples of Potentially Negative Coping Strategies
•	 Withdrawal from social activities
•	 Avoiding substantive social interactions
•	 Leaving employment
FIGURE 2. Coping Strategies to Address Cognitive  
Impairment After Cancer
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cognitive behavioral training (Cherrier et 
al., 2013; Ferguson et al., 2007, 2012; Go-
edendorp, Knoop, Gielissen, Verhagen, 
& Bleijenberg, 2014; Locke et al., 2008; 
McDougall, 2001; McDougall, Becker, 
Acee, Vaughan, & Delville, 2011; Schuurs 
& Green, 2012; Sherer, Meyers, & Bergl-
off, 1997), cognitive training (Gehring 
et al., 2009; Hassler et al., 2010; Kesler 
et al., 2013; Miotto et al., 2013; Poppel-
reuter, Weis, & Bartsch, 2009; Von Ah et 
al., 2012; Zucchella et al., 2013), electro-
encephalography (EEG)/neurofeedback 
(Alvarez, Meyer, Granoff, & Lundy, 2013), 
exercise (Baumann et al., 2011; Korstjens, 
Mesters, van der Peet, Gijsen, & van den 
Borne, 2006; Oh et al., 2011; Reid-Arndt, 
Matsuda, & Cox, 2012; Schwartz et al., 
2002), ginkgo biloba (Attia et al., 2012; 
Barton et al., 2012), meditation (Milbury 
et al., 2013), mindfulness-based stress 
reduction (Hoffman et al., 2012), natural 
restorative environment (Cimprich, 1993; 
Cimprich & Ronis, 2003), structured re-
habilitation (Rottmann et al., 2012), and 
vitamin E (Chan, Cheung, Law, & Chan, 
2004; Jatoi et al., 2005). 
The emerging empirical research 
has demonstrated the most support for 
nonpharmacologic treatments, such as 
cognitive training. In fact, the Oncol-
ogy Nursing Society’s Putting Evidence 
Into Practice (PEP) resource identified 
cognitive training programs as likely 
to be effective for addressing cognitive 
impairment in survivors (Von Ah et al., 
2014). However, additional research is 
needed to fully understand the benefits 
of interventions designed to reduce stress 
and improve attention, such as cognitive 
behavioral training, mindfulness-based 
stress reduction, and exercise. Research 
regarding pharmacologic treatments has 
yielded equivocal results, and those treat-
ments need further investigation to ex-
plore their effectiveness (Von Ah et al., 
2014).
Nursing Implications and 
Need for Future Research 
Oncology nurses are in a prime posi-
tion to address cognitive changes after 
cancer and cancer treatment. Nurses 
need to recognize the cancer- and non-
cancer–related factors that may place 
a survivor at higher risk for cognitive 
changes. In addition, nurses must fully 
TABLE 1.  Pharmacologic Interventions for Cognitive Impairment in Survivors
Study Intervention Findings
Donepezil
Jatoi et  
al., 2005a
5 mg per day for four weeks in-
creased to 10 mg per day plus vita-
min E 1,000 IU per day
No treatment effect
Shaw et  
al., 2006
5 mg per day for six weeks; 10 mg 
per day for 18 weeks; followed by six 
weeks washout
Improvement on attention and concentra-
tion, verbal memory, and figural memory
Methylphenidate/Dexmethylphenidate (MPH/dMPH)
Bruera et 
al., 1992
10 mg per day for two days Improvement in alertness, attention, and 
memory
Butler et  
al., 2007
10–30 mg per day during and eight 
weeks after radiation therapy
No treatment effect
Escalante  
et al., 2014
18 mg per day for two weeks fol-
lowed by placebo for two weeks
Improvement in speed of processing and 
recall
Gagnon et 
al., 2005
10 mg test dose; increased to 20 mg 
per day and increased by 5 mg per day 
until resolution of delirium or maxi-
mum tolerated dose
Improvement in overall cognitive func-
tioning alertness, psychomotor function-
ing, and slurred speech
Gehring et 
al., 2012a
20 mg per day MPH or 18 mg per 
day sustained release MPH versus 
200 mg per day modafinil for four 
weeks 
Improvement in speed of processing and 
executive function; MPH improved at-
tention, modafinil improved processing 
speed
Lower et  
al., 2009
10 mg per day No treatment effect
Mar Fan  
et al., 2008
10 mg per day for one week; if toler-
ated, increase up to 20 mg per day
No treatment effect
Meyers et 
al., 1998
10 mg per day; increase by 5 mg 
BID until response or dose-limiting 
toxicity
Improvement in psychomotor speed, 
memory, visual-motor function, executive 
function, motor speed, and dexterity
Schwartz  
et al., 2002a
20 mg per day, long-acting, for four 
months and 15–20 minutes of exercise
Improvement in perceived mental health 
and executive function in MPH group
Memantine
Brown et 
al., 2013
Total dose of 20 mg per day Reduced decline in memory processing 
speed and executive function; no im-
provement in delayed recall
Modafinil
Blackhall  
et al., 2009
100 mg per day for two weeks; 200 
mg per day for two weeks
Improvement in cognitive flexibility; no in-
tervention effect on verbal learning, mem-
ory, verbal fluency, motor and eye-hand 
coordination, attention, or motor speed
Gehring  
et al., 2012
20 mg per day MPH or 18 mg per day 
sustained release MPH versus 200 
mg per day modafinil for four weeks
Improvement in speed of processing and 
executive function; MPH improved atten-
tion, modafinil improved processing speed
Kohli et  
al., 2009
200 mg day for four weeks; respond-
ers continued 200 mg day or placebo 
for four weeks
Improvement in speed of memory and ep-
isodic memory but not working memory
Lundorff et 
al., 2009
200 mg per day for four days Improvement noted in attention and psy-
chomotor speed
a Indicates interventions that combine pharmacologic and nonpharmacologic approaches 
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TABLE 2.  Nonpharmacologic Interventions for Cognitive Impairment for Cancer Survivors
Study Intervention Findings
Cognitive-Behavioral Training
Cherrier et al., 2013 Seven one-hour sessions for seven weeks Improvement in perceived cognitive function
Ferguson, McDonald,  
et al., 2007
Memory Attention Adaptation Training (MAAT), 
30–50 minutes for four months
Improvement over time in perceived cognitive functioning, verbal 
memory, attention, and executive psychomotor functioning
Ferguson et al., 2012 MAAT training Improvement in verbal memory
Goedendorp et al., 2014 Individualized training (5–26 sessions, 
—
X    = 12.5,  
SD = 4.7) focused on reducing fatigue
Improvement in perceived concentration; no improvement on 
neuropsychological assessment
Locke et al., 2008 Six sessions of cognitive rehab and six sessions of 
problem-solving therapy for two weeks
Improvement in mood; unable to obtain follow-up on objective 
cognitive functioning
McDougall, 2001 75 minutes, eight sessions for four weeks with MT 
and self-efficacy
Improvement in perceived cognitive functioning; memory effi-
cacy, and metamemory; no improvement in memory performance
McDougall et al., 2011 30 minutes per week for eight weeks of MT with 
four, two-hour booster sessions
Improvement in perceived cognitive functioning and visual 
memory
Schuurs & Green, 2012 Two hours per week for four weeks; includes psycho-
education and problem-solving approaches
Improvement in immediate (short-term) and delayed memory, 
visuospatial skills, and language and attention; these were sus-
tained at three months postintervention except for language and 
attention.
Cognitive Training
Gehring et al., 2009 Two hours per week for six weeks of cognitive train-
ing
Improvement in perceived cognitive function immediately and 
at six months postintervention; improvement in attention and 
memory at six months postintervention only
Hassler et al., 2010 90 minutes per week for 10 weeks of CT Improvement in learning, perception, concentration, attention, 
memory, retentiveness, and verbal memory
Kesler et al., 2013 48 executive function training sessions for 12 weeks Improvement in cognitive flexibility, verbal fluency, and process-
ing speed
Miotto et al., 2013 Minimum of five 30-minute sessions of semantic 
organizational strategies
Improvement in verbal recall and increased activation
Poppelreuter et al., 2009 Two intervention groups: four one-hour sessions of (a) 
attention and memory training in person or (b) atten-
tion and memory per computer compared to control
No intervention effects
Von Ah et al., 2012 10 one-hour sessions for 6–8 weeks; two groups (MT 
or ST compared to control)
Improvement in perceived cognitive function both groups; MT 
had improvement in immediate and delayed memory, ST had 
improvement in immediate and delayed memory as well as pro-
cessing speed.
Zucchella et al., 2013 16 one-hour sessions for four weeks Improvement in visual attention and verbal memory
EEG/Neurofeedback
Alvarez et al., 2013 20-session neurofeedback regimen Improvement in perceived cognitive function
Exercise Programs: Combined or Alone
Baumann et al., 2011 60 minutes of resistance training two times per week 
for 12 weeks
Improvement in attention and working memory; no improvement 
in verbal memory; no baseline control group
Korstjens et al., 2006 Two-hour sessions two times per week for 12 weeks 
of physical fitness, plus seven two-hour psycho-
education sessions
Improvement in perceived cognitive function
a Interventions that combine pharmacologic and nonpharmacologic approaches  
CT—cognitive training; EEG—electroencephalography; MBSR—mindfulness-based stress reduction; MT—memory training; ST—speed-of-process training
(Continued on the next page)
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assess each survivor for this late and long-term effect of treat-
ment. Survivors often will express concerns regarding memory 
lapses (remembering names, dates, and places), inability to 
concentrate, and difficulty following instructions or completing 
tasks. These concerns should be fully assessed and referred to 
other healthcare professionals (e.g., neuropsychologist, psy-
chiatrist) for evaluation if they disrupt everyday functioning 
(Jansen, 2013). At a minimum, nurses should acknowledge the 
survivors’ cognitive concerns because research has suggested 
that the acknowledgement alone can reduce distress. In addi-
tion, nurses should thoroughly assess and treat other symptoms 
that commonly co-occur with cognitive impairment, such 
as depression and anxiety. Addressing these other co-related 
symptoms may also help ameliorate the perception of cognitive 
impairment. Nurses should be aware of and refer survivors with 
concerns to reputable resources, such as the PEP resource for 
cognitive impairment (www.ons.org/practice-resources/pep/
cognitive-impairment). This site is routinely updated with the 
most relevant empirical research in this area. 
Based on the current research, cognitive training has shown 
to be useful in addressing cognitive impairment and has been 
identified as likely to be effective in improving cognitive impair-
ment in cancer survivors (Von Ah et al., 2014). More research is 
needed, however, to fully identify effective interventions that 
are feasible and cost effective. Much of the current research is 
still limited by the research design (e.g., lack of randomized, 
controlled trials; lack of an attention control comparison group; 
laboratory versus home-based programs), small sample sizes, 
TABLE 2.  Nonpharmacologic Interventions for Cognitive Impairment for Cancer Survivors (Continued)
Study Intervention Findings
Exercise Programs: Combined or Alone (Continued)
Oh et al., 2011 90 minutes per week for 10 weeks of medical qigong Improvement in perceived cognitive function
Reid-Arndt et al., 2012 60 minutes of tai chi two times per week for 10 
weeks
Improvement in perceived cognitive function, immediate and 
delayed memory, verbal fluency, attention, and executive func-
tioning; no control
Schwartz et al., 2002a 15–20 minutes of aerobic exercise four days per 
week with MPH
Improvement in perceived cognitive function (mental health)
Ginkgo biloba
Attia et al., 2012 120 mg per day for 24 weeks; six-week washout Improvement in executive function, nonverbal memory attention, 
and concentration; no control group for practice effects
Barton et al., 2012 120 mg per day No treatment effect
Meditation
Milbury et al., 2013 Tibetan sound meditation for six weeks Improvement in perceived cognitive function, verbal memory, 
and processing speed immediately post-intervention; no im-
provement six months later
MBSR
Hoffmann et al., 2012 Eight-week program of MBSR Improvement in perceived cognitive function–confusion
Natural Restorative Environment
Cimprich, 1993 60–90 minutes per week of walking gardening Improvement in attentional fatigue
Cimprich & Ronis, 2003 120 minutes per week of exposure to the natural 
environment
Improvement in capacity to direct attention
Structured Rehabilitation
Rottmann et al., 2012 Six-day residential course Improvement in perceived cognitive function
Vitamin E
Chan et al., 2004 Vitamin E 2,000 IU per day Improvement in global cognitive functioning, verbal and visual 
memory, and executive functioning; no improvement in attention
Jatoi et al., 2005a Vitamin E 1,000 IU per day and donepezil for four 
weeks
No treatment effect
a Interventions that combine pharmacologic and nonpharmacologic approaches  
CT—cognitive training; EEG—electroencephalography; MBSR—mindfulness-based stress reduction; MT—memory training; ST—speed-of-process training
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limited sample diversity (mostly conducted in brain tumor 
or breast cancer survivors with well-educated and Caucasian 
participants), and lack of assessment using standardized neuro-
psychological tests. Research in this area is vital to fully address 
cancer- and cancer treatment–related cognitive impairment, 
which has been shown to be a prevalent, bothersome, and 
potentially debilitating symptom. 
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